Welcome to this UK AstraZeneca produced and funded website
This website is intended for UK Healthcare Professionals only.
The website contains both promotional and non-promotional content.
If you are a patient or a carer of a patient prescribed an AstraZeneca product, please visit myazmed.co.uk
For any other UK residents please visit astrazeneca.co.uk
This website is intended for UK Healthcare Professionals only. Other UK residents please visit astrazeneca.co.uk
A COPD exacerbation is an acute-onset, sustained worsening of patient’s symptoms from their usual stable state, going beyond normal day-to-day variations.1
COPD exacerbations, characterized by sudden worsening of symptoms such as increased breathlessness, cough, and sputum production, lead to significant deterioration in lung function.1,2 Following an exacerbation, lung function may not recover to pre-exacerbation levels.2
The impact of COPD exacerbations on COPD outcomes
With each exacerbation, studies have shown decreased time between the first exacerbation, and subsequent exacerbations or an increased risk of premature mortality.4,5
Research indicates a vicious cycle where one exacerbation increases the likelihood of further exacerbations. This is supported by findings showing that exacerbations reduce lung function over time, making patients more susceptible to additional episodes.4,5
The impact of COPD exacerbations on COPD outcomes
Patients at greatest risk of future exacerbations were those who had a previous history of exacerbations5
a. A total of 99,574 patients with COPD were identified from the UK Clinical Practice Research Datalink to investigate the natural history of COPD exacerbations over 10 years of follow-up6
b. Based on adjusted HRs for comparison of a future severe exacerbation in patients with one previous moderate exacerbation versus those without an exacerbation during a case-control study6
The impact of COPD exacerbations on future cardiopulmonary events
COPD-associated cardiopulmonary risk. Figure adapted from Singh, D., & Gale, C. P. et al Adv Ther (2024) with permission from Springer Nature.8
Exacerbations of COPD not only reduce lung function but also increase the risk of cardiovascular events, with this risk remaining elevated for up to a year. The period immediately following a COPD exacerbation is critical for clinical intervention to prevent future cardiovascular events.9
The pathophysiological links between COPD and cardiovascular disease are believed to be related to:
Inflammation10-13
Hyperinflation11,14-16
Hypoxemia17
Moderate exacerbation: unadjusted HR, 2.11 (95% CI, 2.06–2.17); adjusted HR, 1.67 (95% CI, 1.62–1.72). Severe exacerbation: unadjusted HR, 4.07 (95% CI, 3.94–4.21); adjusted HR, 3.18 (95% CI, 3.06–3.29).
AECOPD, acute exacerbations of chronic obstructive pulmonary disease; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CV, cardiovascular; HR, hazard ratio; N, number of patients.
GB-60847 | November 2024
TRIXEO and AEROSPHERE are registered trademarks of the AstraZeneca group of companies.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling 0800 783 0033.
This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.
